Small Pharma Analyst
Growth, long/short equity, biotech, healthcare

What's Next For Durata?

Durata (NASDAQ:DRTX) is a small biopharmaceutical company engaged in the development of antibiotic drugs. The company is headed toward an incredibly important milestone - the likely NDA approval of their first drug, Dalvance (dalvabancin), by the end of May. As followers of this company are well aware, the FDA advisory committee recommended approval of dalvabancin back in March by a 12 - 0 vote. In a recent article on Durata by Seeking Alpha contributor Tri Duong, a positive vote by the Ad Com leads to a 91% approval by the FDA. Thus, approval probability is very high and only an administrative glitch would likely delay it.

Dalvance - A Very Brief Background

Dalvance (dalbavancin) is a lipoglycopeptide antibiotic...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details